Gautam Borthakur

Statistics

Publications

Citations

903

H-Index

Active since

2007

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas Health Science Center at Houston

Dana-Farber Cancer Institute

Sylvester Comprehensive Cancer Center

University of Miami

Gautam Borthakur is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematologic malignancy therapy, and chemotherapy.

Publications per year

2007–2024

Publications

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Nitin Jain, Jayastu Senapati, Beenu Thakral et al. · Blood Advances · 2022 · 76 citations · Full text

Life Sciences, Immunology, Pharmacology +17

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, Hagop M. Kantarjian, Naval Daver et al. · Blood · 2017 · 73 citations

Medicine, Oncology, Pharmacology +15

Targeted therapy with the mutant <i>IDH2</i> inhibitor enasidenib for high-risk <i>IDH2</i>-mutant myelodysplastic syndrome

Courtney D. DiNardo, Sangeetha Venugopal, Curtis A. Lachowiez et al. · Blood Advances · 2022 · 64 citations · Full text

Medicine, Oncology, Pharmacology +14

Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis

Naval Daver, Jörge E. Cortes, Kate J. Newberry et al. · Haematologica · 2015 · 62 citations · Full text

Medicine, Hematology, Pharmacotherapy +10

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Jayastu Senapati, Abhishek Maiti et al. · Blood · 2022 · 62 citations

Medicine, Pharmacology, Pharmacotherapy +12

1–5 of 33